A double-blind, randomized, placebo-controlled, two-centre, phase IIa pharmacodynamic cross-over study to assess the effect of AZD2516 on the total number of reflux episodes in healthy male volunteers

Registry ID

EUCTR2010-018608-98

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

AstraZeneca AB

Start date

2010-06-09

Last update

2026-08-16

Conditions

• Gastroesophageal Reflux Disease (GERD)

Summary

The primary study objective is to assess the effect of AZD2516, measured as reduction in the total number of reflux episodes during a 3-hour post meal period compared to placebo.

Locations

• , , Belgium

Related clinical trials

• Indiana University Gastrointestinal Motility Diagnosis Registry
• Esophageal Cancer Risk Registry
• Performance and Safety of Afluxin® in Patients With Gastroesophageal Reflux Disease
• Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
• Clinical Study Evaluating The Role of Vonoprazan Versus Pantoprazole in Patients With Gastroesophageal Reflux Disease

View on source registry